Patents Assigned to Guangzhou Cellprotek Pharmaceutical Co., Ltd.
  • Publication number: 20210060035
    Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.
    Type: Application
    Filed: December 28, 2018
    Publication date: March 4, 2021
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Yijun HUANG, Wei YIN, Suizhen LIN
  • Publication number: 20200392250
    Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 17, 2020
    Applicant: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Wei YIN, Yuan LI, Bingzheng LU, Longxiang SHENG
  • Patent number: 10835539
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: November 17, 2020
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Publication number: 20200330483
    Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.
    Type: Application
    Filed: December 28, 2018
    Publication date: October 22, 2020
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Wei YIN, Longxiang SHENG, Bingzheng LU, Yijun HUANG, Suizhen LIN
  • Patent number: 10357500
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Patent number: 9944672
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 17, 2018
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
    Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
  • Patent number: 9944673
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 17, 2018
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
    Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
  • Patent number: 9688716
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: June 27, 2017
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
    Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
  • Patent number: 9428539
    Abstract: The present invention discloses compound 2?,3?,5?-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 30, 2016
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Jingxia Zhang, Suizhen Lin, Minyu Xie